International Stem CellISCO -10.50%24 Quick Ratio is 0.40 as of Mar. 2026, which is 7% below its 10-year median of 0.43. GuruFocus rates ISCO with a GF Score™ of 24/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,410 Biotechnology companies, International Stem Cell ranks worse than 91.13% on this metric.
International Stem Cell has a quick ratio of 0.40. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for International Stem Cell's Quick Ratio or its related term are showing as below:
ISCO'
s Quick Ratio Range Over the Past 10 Years
Min: 0.22 Med: 0.43 Max: 1.15
Current: 0.4
During the past 13 years, International Stem Cell's highest Quick Ratio was 1.15. The lowest was 0.22. And the median was 0.43.
ISCO's Quick Ratio is ranked worse than 91.13% of 1410
companies
in the Biotechnology industry
Industry Median: 3.6
vs ISCO: 0.40
International Stem Cell (OTCPK:ISCO) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
International Stem Cell Quick Ratio Related Terms
International Stem Cell Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, International Stem Cell's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
International Stem Cell Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, International Stem Cell's Quick Ratio distribution charts can be found below:
* The bar in red indicates where International Stem Cell's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
International Stem Cell's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Stem Cell (ISCO) has a Quick Ratio of 0.40 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on International Stem Cell and its competitors. This is near median its historical median of 0.43. Over the past decade, International Stem Cell's Quick Ratio has ranged from 0.22 to 1.15. According to the industry distribution chart, International Stem Cell ranks #1285 out of 1410 companies in the Biotechnology industry, placing it in the top 91.1%.
Is International Stem Cell's Quick Ratio too high?
International Stem Cell's current Quick Ratio of 0.40 is near median its 10-year median of 0.43. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 1.15. The Biotechnology industry median Quick Ratio is 3.60. International Stem Cell's value of 0.40 is 88.9% below this industry median. Based on the distribution chart, International Stem Cell ranks #1285 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, International Stem Cell has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's Quick Ratio compare to ZVSA and AXIM?
According to the Biotechnology industry distribution chart, International Stem Cell ranks #1285 out of 1410 companies for Quick Ratio. This places International Stem Cell in the lower half of its industry. The industry median Quick Ratio is 3.60. International Stem Cell's value of 0.40 is 88.9% below this benchmark. Historically, International Stem Cell's own Quick Ratio has ranged from 0.22 to 1.15 over the past decade. While the company's 10-year median is 0.43 vs. the industry median of 3.60, International Stem Cell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. International Stem Cell's current Quick Ratio of 0.40 is 88.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on International Stem Cell and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. International Stem Cell's current Quick Ratio is 0.40, which is near median its own 10-year median of 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.18 — trading 37.7% above its estimated fair value. The current Quick Ratio is 0.40, which is near median its 10-year median of 0.43 and 88.9% below the Biotechnology industry median of 3.60. International Stem Cell's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For International Stem Cell (ISCO), the current Quick Ratio is 0.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is International Stem Cell (ISCO) Overvalued in 2026?
Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued.
The current stock price of $0.18 is trading 37.7% above its estimated GF Value™ of $0.13.
GuruFocus considers International Stem Cell to be Significantly Overvalued.
Key valuation signals for ISCO:
Quick Ratio: 0.40 (near median its 10-year median of 0.43)
GF Value™: $0.13 vs. price of $0.18 (37.7% above fair value)
Industry Position: 88.9% below the Biotechnology median (#1285 of 1410)
No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
24GF Score
Get the complete analysis for ISCO
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISCO has been successfully added to your 
